Compare HSBC Holdings plc (HSBC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs ResMed Inc. — how do they compare? HSBC Holdings plc trades at $92.81 (market cap $311.92B), while ResMed Inc. trades at $229.75 (market cap $31.89B). The key difference: HSBC Holdings plc is far larger — about 9.8× ResMed Inc.'s market cap, and HSBC Holdings plc pays the higher dividend (4.05%). Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and ResMed Inc. for 51 Days on average.
| HSBC | RMD | |
|---|---|---|
Market Cap | $311.92B | $31.89B |
Volume | 3,546,658 | 618,314 |
Sector | Financials | Health |
52-Week High | $107.86 | $277.88 |
52-Week Low | $65.67 | $182.82 |
Typical Hold Time | 36 Days | 51 Days |
Enterprise Value | $222.19B | $31.24B |
Dividend Yield | 4.05% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.80, down 0.97% with bearish technical signals. The stock shows strong profitability with 34.54% net margin and reasonable valuation at 13.23 P/E. Recent earnings were mixed with Q2 beat but Q1 miss. Analyst sentiment is cautious with 38% buy ratings. The bank is expanding in technology banking and US wealth services while restructuring European operations.
HSBC offers value with solid fundamentals but faces near-term headwinds from technical weakness and mixed earnings performance. Growth opportunities in Asian markets and wealth management balance risks from European restructuring and CFO transition in 2027.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
